Moscow says India may replace West in Russian pharmaceuticals market

The newly appointed Russian envoy added that India is a "world pharmacy" and a leading manufacturer of drug copies that are no worse than the original.

pharma
ANI Asia
2 min read Last Updated : Mar 18 2022 | 8:36 PM IST

Indian pharmaceutical companies may replace Western manufacturers leaving the Russian market, Russian envoy to India Denis Alipov said on Friday.

"The withdrawal of many Western companies from the Russian market and those niches that have been vacated may actually be occupied by Indian companies in many industries, in particular, in pharmaceuticals," Alipov told the Rossiya 24 broadcaster, as quoted by Sputnik news agency.

The newly appointed Russian envoy added that India is a "world pharmacy" and a leading manufacturer of drug copies that are no worse than the original.

India's Vaccine Maitri initiative last year reinforced its credentials as the "pharmacy of the world". World leaders publicly commended India's efforts to rapidly expand vaccines production and supplies at critical junctures of the pandemic.

This decision to replace manufacturers in pharmaceutical comes at a time when Russia has been bombarded with sanctions from Western countries. Now Russia is looking to enhance economic engagement with countries non-European countries.

Earlier this month, Alipov had said that Moscow has welcomed the independent foreign policy of India amid the Russia-Ukraine conflict.

Touching upon the relations with India, Alipov said, "Prime Minister (Modi) and the Indian leadership meet the consistent independent policy of the state in international affairs. We have repeatedly stated that we have welcomed the independent foreign policy of India and strengthening its role and its influence in the international arena."

The Russian envoy also hailed the Indian foreign policy stand on the ongoing Russia-Ukraine conflict.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Russia Ukraine ConflictIndia RussiaUkraine

First Published: Mar 18 2022 | 8:36 PM IST

Next Story